NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology

NanoView Biosciences, a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center (“BIDMC”) to study the involvement of biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (“ICIT”) for cancer. The ExoPD-L1 to Predict Immunotherapy Response in Cancer (“EPIC”) Study will specifically investigate Programmed Death-Ligand 1 (“PD-L1”) and status of disease as well as response to therapy.

Exosomes are small extracellular vesicles, 50 – 150 nm in size, that facilitate communication between cells by shuttling proteins, lipids and nucleic acids. NanoView’s platform technology, ExoView®, will be used in the EPIC Study to characterize PD-L1 and other biomarkers carried by exosomes in plasma samples from patients undergoing ICIT.

“NanoView is excited to collaborate with BIDMC through the EPIC Study,” stated Jerry Williamson, CEO of NanoView.  “We are pleased that BIDMC will help evaluate data from our ExoView platform to better understand the role that exosome-associated biomarkers play in disease status and therapeutic response for cancer patients.”

Bruno Bockorny, M.D., an oncologist from BIDMC, will serve as the Study Principal Investigator. Co-investigators from the Division of Medical Oncology and Immunotherapy Institute at BIDMC will also participate.

“Disease status and response to therapy are difficult to predict for patients involved in ICIT and our aim is to continue to look for better clues that will deliver better outcomes,” stated Dr. Bockorny.

“Our current ability to predict which patients are most likely to benefit from immunotherapy is very limited,” said Vassiliki Boussiotis, M.D., one of the co-investigators from BIDMC. “Even for cancer types with significant level of PD-L1 expression, frequently, there is discordance between PD-L1 expression level and response to treatment. Our study is looking at a novel way of determining responders through a blood test.”

“One of the most urgent challenges for the care of patients with advanced cancer is the identification of novel biomarkers to help select which cases will benefit the most from immune checkpoint inhibitors,” said BIDMC co-investigator Daniel Costa, M.D., Ph.D. “Our goal with this innovative research is to advance the field of immuno-oncology and precision medicine.”

“Through the collaboration with leading institutes such as BIDMC, NanoView is expanding the utility of its products for clinical research in the field of extracellular vesicles”, stated George Daaboul, CSO of NanoView. “Our ExoView platform will allow detection of circulating immune-associated ligands such as PD-L1 and other regulatory markers, giving us better insight into the immune response without the need for tissue biopsy.” NanoView’s goal is to enable the future development of diagnostic, prognostic and therapeutic applications involving biological nanoparticles such as exosomes.

Source – PR Newswire

Leave a Reply

Your email address will not be published. Required fields are marked *